In the AD patient brain, the activity and protein and mRNA levels of PP-2A were all decreased, and the expression of an endogenous PP2A inhibitor (Inhibitor 2 of Protein Phosphatase 2A, I2PP2A) was increased [31, 32]. Here, PTPA is linked to Alzheimer disease.